Gofen & Glossberg’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $20.6M | Sell |
227,555
-4,434
| -2% | -$373K | 0.53% | 48 |
|
|
2022
Q3 | $17.6M | Sell |
231,989
-2,457
| -1% | -$204K | 0.5% | 51 |
|
|
2022
Q2 | $19.8M | Sell |
234,446
-13,373
| -5% | -$1.17M | 0.53% | 51 |
|
|
2022
Q1 | $21.7M | Sell |
247,819
-16,569
| -6% | -$1.43M | 0.5% | 51 |
|
|
2021
Q4 | $23.1M | Sell |
264,388
-653
| -0.2% | -$54.2K | 0.5% | 50 |
|
|
2021
Q3 | $21.7M | Sell |
265,041
-2,100
| -0.8% | -$189K | 0.51% | 50 |
|
|
2021
Q2 | $24.4M | Sell |
267,141
-222
| -0.1% | -$19.8K | 0.58% | 45 |
|
|
2021
Q1 | $22.9M | Buy |
267,363
+6,157
| +2% | +$553K | 0.59% | 47 |
|
|
2020
Q4 | $24.7M | Buy |
261,206
+558
| +0.2% | +$48.8K | 0.68% | 39 |
|
|
2020
Q3 | $22.7M | Buy |
260,648
+5,929
| +2% | +$514K | 0.7% | 38 |
|
|
2020
Q2 | $22.2M | Hold |
254,719
| – | – | 0.75% | 39 |
|
|
2020
Q1 | $21M | Buy |
254,719
+4,226
| +2% | +$377K | 0.82% | 37 |
|
|
2019
Q4 | $23.7M | Buy |
250,493
+1,683
| +0.7% | +$151K | 0.75% | 39 |
|
|
2019
Q3 | $21.6M | Sell |
248,810
-740
| -0.3% | -$66.4K | 0.73% | 43 |
|
|
2019
Q2 | $22.8M | Sell |
249,550
-29,435
| -11% | -$2.49M | 0.78% | 36 |
|
|
2019
Q1 | $24M | Buy |
278,985
+963
| +0.3% | +$77.3K | 0.85% | 35 |
|
|
2018
Q4 | $21.4M | Sell |
278,022
-686
| -0.2% | -$53.4K | 0.85% | 38 |
|
|
2018
Q3 | $21.5M | Sell |
278,708
-2,469
| -0.9% | -$183K | 0.74% | 42 |
|
|
2018
Q2 | $19M | Buy |
281,177
+3,441
| +1% | +$237K | 0.71% | 43 |
|
|
2018
Q1 | $20.1M | Sell |
277,736
-5,157
| -2% | -$393K | 0.75% | 41 |
|
|
2017
Q4 | $21.3M | Buy |
282,893
+445
| +0.2% | +$33.6K | 0.76% | 40 |
|
|
2017
Q3 | $21.7M | Sell |
282,448
-6,337
| -2% | -$479K | 0.81% | 35 |
|
|
2017
Q2 | $21.6M | Sell |
288,785
-3,889
| -1% | -$276K | 0.82% | 34 |
|
|
2017
Q1 | $19.5M | Sell |
292,674
-23,819
| -8% | -$1.59M | 0.76% | 39 |
|
|
2016
Q4 | $20.7M | Sell |
316,493
-5,392
| -2% | -$350K | 0.84% | 33 |
|
|
2016
Q3 | $22.8M | Sell |
321,885
-5,078
| -2% | -$370K | 0.94% | 31 |
|
|
2016
Q2 | $24.2M | Buy |
326,963
+4,167
| +1% | +$288K | 1.01% | 29 |
|
|
2016
Q1 | $21M | Buy |
322,796
+2,113
| +0.7% | +$144K | 0.89% | 30 |
|
|
2015
Q4 | $24.7M | Buy |
320,683
+6,247
| +2% | +$496K | 1.07% | 26 |
|
|
2015
Q3 | $25.9M | Sell |
314,436
-3,402
| -1% | -$303K | 1.18% | 24 |
|
|
2015
Q2 | $28M | Buy |
317,838
+4,957
| +2% | +$455K | 1.18% | 24 |
|
|
2015
Q1 | $27.6M | Sell |
312,881
-1,367
| -0.4% | -$121K | 1.19% | 26 |
|
|
2014
Q4 | $26.1M | Sell |
314,248
-2,043
| -0.6% | -$169K | 1.12% | 22 |
|
|
2014
Q3 | $26.7M | Buy |
316,291
+1,089
| +0.3% | +$88.1K | 1.18% | 21 |
|
|
2014
Q2 | $25.6M | Buy |
315,202
+983
| +0.3% | +$77.3K | 1.13% | 22 |
|
|
2014
Q1 | $23.4M | Buy |
314,219
+2,486
| +0.8% | +$181K | 1.09% | 21 |
|
|
2013
Q4 | $22.5M | Buy |
311,733
+6,052
| +2% | +$421K | 1.05% | 23 |
|
|
2013
Q3 | $21M | Buy |
305,681
+4,767
| +2% | +$315K | 1.08% | 22 |
|
|
2013
Q2 | $19.1M | Buy |
+300,914
| New | +$19.6M | 1.03% | 22 |
|
Other funds holding NVS
Gofen & Glossberg's NVS Position: Q4 2022 in Review
Gofen & Glossberg reduced its Novartis (NVS) stake by 1.9% in Q4 2022, selling an estimated $373K and leaving 227,555 shares worth $20.6M. The position accounts for 0.53% of the portfolio, ranked #48.
Gofen & Glossberg first reported a position in NVS in Q2 2013 and has held it in 39 quarters since. The position peaked at $28M in Q2 2015. 1,183 funds tracked by Wall St. Rank hold NVS as of Q4 2022.
- Gofen & Glossberg held 227,555 shares of Novartis worth $20.6M as of Q4 2022.
- Gofen & Glossberg sold 4,434 Novartis shares in Q4 2022, an estimated $373K.
- Novartis made up 0.53% of Gofen & Glossberg's portfolio in Q4 2022, its #48 holding.
- Gofen & Glossberg first reported a position in Novartis in Q2 2013 and has held it in 39 quarters since.
- Gofen & Glossberg's Novartis position peaked at $28M in Q2 2015.
- 1,183 funds tracked by Wall St. Rank held Novartis as of Q4 2022.
Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.